Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study

Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4

Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA, 302, 1993, 10.1001/jama.2009.1619

Badimon, 1990, Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit, J Clin Invest, 85, 1234, 10.1172/JCI114558

Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice, Circulation, 100, 1816, 10.1161/01.CIR.100.17.1816

Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628

Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797

Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579

Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955

Frikke-Schmidt, 2008, Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease, JAMA, 299, 2524, 10.1001/jama.299.21.2524

Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2

Rothblat, 1999, Cell cholesterol efflux: integration of old and new observations provides new insights, J Lipid Res, 40, 781, 10.1016/S0022-2275(20)32113-1

Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N Engl J Med, 364, 127, 10.1056/NEJMoa1001689

Parish, 2009, The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls, Eur Heart J, 30, 2137, 10.1093/eurheartj/ehp221

Li, 2013, Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks, Arterioscler Thromb Vasc Biol, 33, 1696, 10.1161/ATVBAHA.113.301373

Rohatgi, 2014, HDL Cholesterol efflux capacity and incident cardiovascular events, N Engl J Med, 371, 2383, 10.1056/NEJMoa1409065

Day, 1999, EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer, Br J Cancer, 80, 95

Boekholdt, 2004, Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study, Circulation, 110, 1418, 10.1161/01.CIR.0000141730.65972.95

de la Llera-Moya, 2010, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages, Arterioscler Thromb Vasc Biol, 30, 796, 10.1161/ATVBAHA.109.199158

Easton, 1991, Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group, Stat Med, 10, 1025, 10.1002/sim.4780100703

Sankaranarayanan, 2011, A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol, J Lipid Res, 52, 2332, 10.1194/jlr.D018051